Navigation Links
AAOMS Updates BRONJ Position Paper
Date:1/22/2009

ROSEMONT, Ill., Jan. 22 /PRNewswire-USNewswire/ -- The American Association of Oral and Maxillofacial Surgeons has revised its 2006 landmark position paper on Bisphosphonate-Related Osteonecrosis of the Jaw to reflect the most current research and thought on this condition. BRONJ appears as a non-healing exposed bone in the maxillofacial region and may affect patients undergoing intravenous cancer-related bisphosphonate therapy or more rarely, patients treated with oral or IV bisphosphonates for osteoporosis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO)

Written by the members of the distinguished AAOMS Task Force on BRONJ who prepared the original paper, the 2009 BRONJ Position Paper updates the staging and management strategies for BRONJ, and highlights the status of basic science research relating to this condition.

The 2009 Position Paper retains the case definition of BRONJ:

1. The patient is or has been treated with a bisphosphonate.

2. Exposed bone has been present in the maxillofacial region for more than eight weeks; and

3. There is no history of radiation therapy to the jaws.

While there is strong evidence supporting an association between IV bisphosphonate therapy for cancer-related conditions and BRONJ, the 2009 BRONJ Position Paper stresses that the relationship between oral or IV bisphosphonates for treating osteoporosis and BRONJ is more difficult to establish.

Specifically, the 2009 BRONJ Position Paper observes that the risk of developing BRONJ is linked to:

1. The potency the bisphosphonate used in therapy; and

2. The length of exposure to bisphosphonates.

Other factors that may increase the risk of developing BRONJ include:

  • A history of inflammatory dental disease,
    '/>"/>

SOURCE American Association of Oral & Maxillofacial Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
2. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
3. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
4. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
5. Genmab Announces Updates on Phase III Cancer Studies
6. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. BioCryst Updates Peramivir Clinical Development Plan
11. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 ... BVXV) today announced it received the statistical analysis of results ... (M-001), administered in the BVX-005 phase II trial which took ... strains which did not exist at the time of the ... strain that caused the epidemic in the United ...
(Date:8/3/2015)... 3, 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... an exclusive licensing agreement to develop and commercialize multiple ... Limited, a holding company for premier antibody development and ... Under the terms of the agreement, Sorrento ... for the North American, European and Japanese market. Each ...
(Date:7/31/2015)... 31, 2015  Physicians and payers alone do ... market. Patients are better informed and getting increasingly ... therapies. This shift in power is reshaping the ... patient-focused marketing. As part of this ... it,s important to educate, communicate and engage patients ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... solutions for drugs, biologics and consumer health products, today welcomed the announcement by ... OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today ... management solution, as well as announced the date of its next major release. ... of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... of it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive ... leaders from healthcare organizations with access to the tactics, techniques and practices required ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article ... Stem Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" ... to the report, the new study showed that harvesting stem cell-rich bone marrow from ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... firm, announced today that Joe Williams has joined its growing California employee benefits ... HUB's differentiated service model to his clients. Mr. Williams will be joining the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... too many clinicians still using unproven treatments , , ... and teens, individual and group cognitive behavioral therapy ... and other trauma symptoms, say U.S. researchers who ... subject. , However, despite the proven effectiveness of ...
... a criminal plea and pay $425 million to resolve ... by the Food and Drug,Administration (FDA), the Justice Department ... Cephalon employees and filed under,the qui tam provisions of ... in a scheme to market Gabitril, Actiq and Provigil ...
... Food Prices on the Rise New Tools to Help Make ... finance expert Suze Orman,is the latest celebrity to join the ... their health. With rising food costs, many,families are economizing on ... nutrition. At about 25 cents per 8 ounce glass, on ...
... In a letter to Dr. Mary S. ... ) board,s Governance Committee, the,CtW Investment Group questions ... Walgreens and challenges the arguments put forward by ... of Longs. Citing analysis prepared by expert anti-trust ...
... Pa., Sept. 29 Herley Industries,Inc. (Nasdaq: ... England division in,Woburn, Massachusetts, has a contract totaling ... NY, for the manufacture of,complex switch filter assemblies ... ("ESM") system., The MH-60R Multi-Mission Helicopter (MMH) ...
... LegalView recently informed mesothelioma blog readers of improper removal of asbestos ... risk for developing mesothelioma cancer. The city used an unapproved "wet ... asbestos dust once the water evaporates. , ... Denver, ...
Cached Medicine News:Health News:Cognitive Behavioral Therapy Best for Traumatized Youths 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 3Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 4Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 5Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 2Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 3Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 2Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 3Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 4Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 5Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 6Health News:Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: